For Researchers

Today’s research can lead to tomorrow’s breakthroughs. In this section, you’ll learn about research funding opportunities, new AFTD initiatives, and more.

Accelerating Drug Discovery for FTD

Through this program, AFTD and the Alzheimer’s Drug Discovery Foundation (ADDF) seek to accelerate drug discovery by supporting research focused on the identification and preclinical testing of promising compounds.

Priority areas for this program include:

  • Development and testing of high-throughput screening assays.
  • Identification and testing of potentially disease-modifying therapies, including:
    • Medicinal chemistry.
    • Pharmacokinetic/pharmacodynamics studies.
  • Testing of novel lead compounds, biologics, or repurposed drugs in a relevant animal model.
  • Development and/or characterization of new model organisms or cellular models to support drug discovery efforts.

Award Details

  • Duration: 1 year, with the possibility of follow-on funding.
  • Amount of award (USD): Typically $100,000 – 150,000.
  • Application of funds: Direct costs only.
  • Additional Information: Visit the ADDF website for additional information.

Who can apply?

  • Investigators at not-for-profit academic and medical research institutions
  • For-profit biotechnology companies that demonstrate a clear need for non-profit funding, both public and private (note that funding to biotechnology companies is typically made as a program-related investment)
  • S. and international investigators

Timeline — 2017 Awards

Accelerating Drug Discovery Timeline

LOIs are reviewed on a rolling basis and can be submitted at any time prior to the deadline.

Applications are reviewed by ADDF and an external Scientific Review Committee, including members of the AFTD Medical Advisory Council. Applications from biotechnology companies will also be reviewed by ADDF’s Business Advisory Board.

Contacts

To further discuss scientific or financial aspects of proposals, please contact:

For more information about the application process, please contact: